Unifying CRM and EWOC designs for phase I cancer clinical trials

DOI10.1016/J.JSPI.2008.07.005zbMath1284.62651OpenAlexW2091515145MaRDI QIDQ1007501

Yong Lin, Pei-Ling Chu, Weichung Joe Shih

Publication date: 20 March 2009

Published in: Journal of Statistical Planning and Inference (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1016/j.jspi.2008.07.005

zbMATH Keywords

maximum tolerated dosecontinual reassessment methoddose-limiting toxicityescalation with overdose controlphase I cancer clinical trial

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Related Items (3)

Dose finding with escalation with overdose control (EWOC) in cancer clinical trials ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ Incoherent dose-escalation in phase I trials using the escalation with overdose control approach

Uses Software

• EWOC

Cites Work

• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Optimal Bayesian-feasible dose escalation for cancer phase I trials
• Design and Analysis of Phase I Clinical Trials
• Prediction Approaches to Sequentially Searching for an Optimal Dose
• Miscellanea. On sequential designs in nonlinear problems
• Non-parametric optimal design in dose finding studies
• Continual reassessment designs with early termination

This page was built for publication: Unifying CRM and EWOC designs for phase I cancer clinical trials